Congress Materials – Rheumatology Winter Clinical Symposium (RWCS 2025)
2025 Rheumatology Winter Clinical Symposium | Feb 12-15 | Maui, HI
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients With Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Philip J. Mease, Alice B. Gottlieb, Iain B. McInnes, Natalie J. Shiff, Emmanouil Rampakakis, Francois Nantel, Jenna Parrett, Frederic Lavie, Proton Rahman
Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Christopher T. Ritchlin, Ennio Lubrano, Maria Sole Chimenti, Evan Leibowitz, Mohamed Sharaf, Emmanouil Rampakakis, Francois Nantel, Frederic Lavie, Atul Deodhar
On-Label Persistence Through 24 Months in Patients with Psoriatic Arthritis Using Guselkumab or Subcutaneous Interleukin-17A Inhibitors
Philip J. Mease, Jessica Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Linda Hou, Shikha Singla, Joseph F. Merola
On-Label Persistence Through 24 Months Among Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous TNF Inhibitors
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Linda Hou, Shikha Singla, Joseph F Merola
VISIBLE: Guselkumab Impact on Psoriatic Arthritis at Week 16 in Participants With Moderate to Severe Psoriasis Across All Skin Tones
Alice B. Gottlieb, Amy McMichael, Tina Bhutani, Olivia Choi, Theodore Alkousakis, Jenny Jeyarajah, Donna Febres, Oyediran Adelakun, Soumya D. Chakravarty, Daphne Chan, Joseph F. Merola
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.